Alpha 2.0
Login Register
» Articles » PMID: 33072103

Immunopathogenesis of COVID-19: Summary and Possible Interventions

Overview
Journal Front Immunol
Specialty Allergy & Immunology
Date 2020 Oct 19
PMID 33072103
Citations 19
Authors
Francois Henri Jacques
Erik Apedaile
Affiliations
Soon will be listed here.
Abstract

Since the onset of the COVID-19 pandemic in the fall of 2019 over 4 million people have been infected and over 280,000 have died (1). Information about the SARS-CoV2 virus is evolving rapidly. At this time there are no interventions proven to be effective for cases infected with SARS-CoV2. Current knowledge about the clinical and laboratory manifestations of COVID-19 infection is reviewed and combined with knowledge about the immunopathogenic mechanisms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV1) and Middle East Respiratory Syndrome (MERS) to formulate theories and suggest possible therapeutic interventions. SARS-CoV2 immunopathogenic mechanisms vary from immunosuppression that initially enables viral escape to a hyperinflammatory immune response. Ultimately therapeutic intervention will be phase dependent.

Citing Articles

Chinese Medicine for Treatment of COVID-19: A Review of Potential Pharmacological Components and Mechanisms.

Xu Q, Yu D, Fan X, Cui H, Dai Q, Zhong X Chin J Integr Med. 2024; 31(1):83-95.

PMID: 38958885 DOI: 10.1007/s11655-024-3909-z.

Evaluation of SARS-CoV-2-Positive Patients with Suspected Reinfection.

Allahverdiyeva A, Agacfidan A, Dogan L, Onel M, Kirkoyun Uysal H, Medetalibeyoglu A Viruses. 2023; 15(11).

PMID: 38005899 PMC: 10675471. DOI: 10.3390/v15112222.

Reduced IL-8 Secretion by NOD-like and Toll-like Receptors in Blood Cells from COVID-19 Patients.

Carreto-Binaghi L, Herrera M, Guzman-Beltran S, Juarez E, Sarabia C, Salgado-Cantu M Biomedicines. 2023; 11(4).

PMID: 37189696 PMC: 10136206. DOI: 10.3390/biomedicines11041078.

Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models.

Lu H, Liu Z, Deng X, Chen S, Zhou R, Zhao R PLoS Pathog. 2023; 19(3):e1011240.

PMID: 36961850 PMC: 10128965. DOI: 10.1371/journal.ppat.1011240.

The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.

Abdulla Z, Al-Bashir S, Alzoubi H, Al-Salih N, Aldamen A, Abdulazeez A Pathogens. 2023; 12(2).

PMID: 36839601 PMC: 9967364. DOI: 10.3390/pathogens12020329.

References
1.
Abdel-Wahab N, Alshawa A, Suarez-Almazor M . Adverse Events in Cancer Immunotherapy. Adv Exp Med Biol. 2017; 995:155-174. DOI: 10.1007/978-3-319-53156-4_8. View
2.
Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View
3.
Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M . Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017; 56:221-228. DOI: 10.1016/j.ijid.2017.01.028. View
4.
Thevarajan I, Nguyen T, Koutsakos M, Druce J, Caly L, van de Sandt C . Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; 26(4):453-455. PMC: 7095036. DOI: 10.1038/s41591-020-0819-2. View
5.
Li X, Geng M, Peng Y, Meng L, Lu S . Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10(2):102-108. PMC: 7104082. DOI: 10.1016/j.jpha.2020.03.001. View